Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Top 10 US Biomedical Research Institutions Involved in Drug Development

By BiotechDaily International staff writers
Posted on 23 Feb 2014
As Big Pharma companies are increasingly slashing their R&D spending, academic research institutions must play a key role in the drug development process, particularly on the preclinical research and drug discovery side.

Whereas many of the research institutions are still doing ample fundamental science research, interest seems to be growing among the universities in repurposing existing drugs or those that never made it into the marketplace because of safety problems, according to recent market research.

FierceBiotech (Washington DC, USA), an online drug development industry publication that monitors biopharmaceutical deals, the US Food and Drug Administration (FDA), and clinical trials, recently reviewed some of the best research institutions in the United States and ranked by them by their level of funding from the US National Institutes of Health (NIH; Bethesda, MD, USA), the largest funder of biomedical research worldwide.

In 2013, funding for biomedical research at these institutions took a hit from sequestration on top of years of budget slashes to the NIH. Out of 10, 7 of those on the list (shown below) lost funding in US fiscal 2013 compared to the same period in 2012. Stanford University, the University of North Carolina at Chapel Hill, and the University of California, San Francisco, were the only 3 among the top 10 to receive a slight cash influx in NIH funding from 2012 to 2013. A 2014 spending bill passed in January 2014 will restore USD 1 billion to NIH compared to fiscal year 2013 postsequester, but that is still below presequester funding levels.

The top ten instituitions: 1. Johns Hopkins University (Baltimore, MD); 2. University of California, San Francisco; 3. University of Washington (Seattle, WA, USA); 4. University of Pennsylvania (Philadelphia); 5. University of Michigan (Ann Arbor); 6. University of Pittsburgh (PA); 7. University of North Carolina at Chapel Hill; 8. University of California, San Diego; 9. Stanford University (Stanford, CA), and 10. Duke University (Durham, NC).

FierceBiotech is a publication of FierceMarkets, a division of Questex Media Group, LLC.

Related Links:

FierceBiotech 
National Institutes of Health



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The European Commission has approved the use of Avastin combined with chemotherapy as a treatment for women with recurrent ovarian cancer (Photo courtesy of Genentech).

Drug for Treatment of Platinum Resistant Recurrent Ovarian Cancer Approved for Use in Europe

For the first time in more than 15 years the European Commission (EC) has approved a new therapeutic option for the most difficult to treat form of ovarian cancer. Ovarian cancer causes more deaths... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel
Image: The DrySyn MULTI converts any standard hotplate stirrer into a high performance reaction block (Photo courtesy of Asynt).

New Reaction Vessel Heating System Is Cleaner and Safer

Biotech and other life science researchers can create a safer, cleaner, and more efficient working environment in their laboratories by switching from oil bath-based heating of reaction vessels to a new... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.